What is Roth Capital’s Forecast for CYCC FY2024 Earnings?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) – Investment analysts at Roth Capital boosted their FY2024 earnings per share (EPS) estimates for Cyclacel Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now anticipates that the biotechnology company will post earnings per share of ($1.95) for the year, up from their prior estimate of ($2.29). Roth Capital has a “Hold” rating on the stock. The consensus estimate for Cyclacel Pharmaceuticals’ current full-year earnings is ($2.29) per share. Roth Capital also issued estimates for Cyclacel Pharmaceuticals’ Q4 2024 earnings at ($0.29) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at $3.67 EPS and FY2028 earnings at $5.49 EPS.

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Friday. They set a “sell” rating for the company.

Cyclacel Pharmaceuticals Stock Down 4.9 %

CYCC opened at $0.37 on Friday. Cyclacel Pharmaceuticals has a 52-week low of $0.35 and a 52-week high of $6.00. The company has a 50 day moving average of $0.85 and a two-hundred day moving average of $1.42. The company has a market cap of $804,100.00, a P/E ratio of -0.04 and a beta of 0.56.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.